Shi Qian is the founder of Singlomics. Singlomics has raised $62M in total funding. Latest round: Series B. Based in Beijing, China.
Shi Qian is the Chief Executive Officer (CEO) of Singlomics (also known as Beijing Danxu Biopharmaceutical Co., Ltd.), a biotechnology company based in Beijing, China. Singlomics focuses on developing innovative antibody drugs for oncology, inflammation, and autoimmune diseases, utilizing a single-cell sequencing technology platform. The company has completed a Series B financing round and has raised a total of $61.81 million. Prior to Singlomics, Shi Qian was the General Manager and Head of Research at Apollomics China and also served as Vice President of Oncology at Crown Bioscience.
Full founder directory · Investor directory · Company funding database · Fundraising library